FT-4202 at Higher Dose Safe and Helpful to Patients in Phase 1 Trial

FT-4202 at Higher Dose Safe and Helpful to Patients in Phase 1 Trial

291445

FT-4202 at Higher Dose Safe and Helpful to Patients in Phase 1 Trial

A higher 600 mg daily dose of FT-4202, a potential disease-modifying oral treatment for sickle cell disease (SCD), was well-tolerated and safe, and improved several measures of red blood cell health after 14 days of treatment, according to recent data from an ongoing Phase 1 trial. These findings support doses being used in the Phase 2/3 Hibiscus study (NCT04624659), a placebo-controlled trial assessing the safety and efficacy of 200 and 400 mg doses of the therapy…

You must be logged in to read/download the full post.